Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
| Autor: | Asya I. Wallach, Ilya Kister, Matthew Tremblay |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Antibodies Monoclonal Humanized law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Randomized controlled trial law Medicine Humans Immunologic Factors Spectrum disorder 030212 general & internal medicine Neuromyelitis optica business.industry Fda approval Neuromyelitis Optica Autoantibody Eculizumab medicine.disease Dermatology chemistry Rituximab Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Neurologic clinics. 39(1) |
| ISSN: | 1557-9875 |
| Popis: | Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing-remitting neuroinflammatory disorder of the central nervous system. Advances in the understanding of NMOSD pathogenesis and identification of the NMO-specific pathogenic anti-AQP4 autoantibody have led to the development of highly effective disease-modifying strategies. Five placebo-controlled, randomized trials for NMOSD have been successfully completed as of 2020. These trials support the efficacy of rituximab and tocilizumab and led to the FDA approval of eculizumab, satralizumab and inebilizumab for NMOSD. Our review provides an update on these evidence-based disease-modifying therapies and discussed the treatment of acute relapses in NMOSD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|